Dr. Clay B. Siegall, Ph.D., co-founder of Seattle Genetics Inc., became its Chief Executive Officer in 2002. According to Bloomsberg, Dr. Siegall been involved in cancer research and related therapeutic drug development for more than 20 years.
Seattle Genetics is a biotechnology company that develops innovative antibody-based therapies that are used in cancer treatment. Currently, Seattle Genetics has only one commercialized drug, Adcetris, which fights lymphomas. However, the company has twelve more drugs under research and has hired 100 employees this year.
Most Glass Door reviews are favorable. Contributors call Seattle Genetics a great company with a small company feel and nice campus. Summer intern opportunities feature activities geared toward interns.
The George Washington Medicine and Health blog recently featured Siegall and reported that he became interested in oncology when his father was diagnosed with brain cancer. My mom was having a tough time. “Partway through my second year of grad school, my dad passed away,” he said.
As an ambitious student, Siegall went on to earn a B.S. in Zoology at the University of Maryland and then he completed a Ph.D. in genetics at George Washington University. Siegall has worked with the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and the National Institutes of Health.
Siegall is listed in a Forbes blog, The Oprahs of Biotech, as one of a few industry leaders people know by first name alone.
Facebook searches for Siegall return a series of photo ops with Seattle Genetics employees at press releases celebrating the company’s accomplishments and grateful family members crediting his contributions to cancer research.
